Whether a project requires narrow spotlights from a tall ceiling or pendants with multipurpose functionality, these ...

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision ...